Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support–free days in patients hospitalized with COVID-19: a randomized clinic... by Lawler, PR, Derde, LPG, van de Veerdonk, FL, Beane, A, Estcourt, LJ, Haniffa, R, Nichol, AD, Pollock, KM

Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine by Thwaites, RS, Uruchurtu, ASS, Negri, VA, Cole, ME, Singh, N, Poshai, N, Jackson, D, Hoschler, K, Baker, T, Scott, IC, Ros, XR, Cohen, ES, Zambon, M, Pollock, KM, Hansel, TT, Openshaw, PJM

Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial by Hodgson, SH, Iveson, P, Larwood, J, Roche, S, Morrison, H, Cosgrove, C, Galiza, E, Ikram, S, Lemm, N-M, Mehdipour, S, Owens, D, Pacurar, M, Schumacher, M, Shaw, RH, Faust, SN, Heath, PT, Pollard, AJ, Emary, KRW, Pollock, KM, Lazarus, R

An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trial by Pollock, KM, Borges, AH, Cheeseman, HM, Rosenkrands, I, Schmidt, KL, Søndergaard, RE, Day, S, Evans, A, McFarlane, LR, Joypooranachandran, J, Amini, F, Skallerup, P, Dohn, RB, Jensen, CG, Olsen, AW, Bang, P, Cole, T, Schronce, J, Lemm, N-M, Kristiansen, MP, Andersen, PL, Dietrich, J, Shattock, RJ, Follmann, F

Antibody responses to Influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib by Liu, Z, Alexander, JL, Eng, KY, Ibraheim, H, Anandabaskaran, S, Saifuddin, A, Constable, L, Seoane, RC, Bewshea, C, Nice, R, D'Mello, A, Jones, GR, Balarajah, S, Fiorentino, F, Sebastian, S, Irving, PM, Hicks, LC, Williams, HRT, Kent, AJ, Linger, R, Parkes, M, Kok, K, Patel, KV, Teare, JP, Altmann, DM, Boyton, RJ, Hart, AL, Lees, CW, Goodhand, JR, Kennedy, NA, Pollock, KM, Ahmad, T, Powell, N

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial by Folegatti, PM, Ewer, KJ, Aley, PK, Angus, B, Becker, S, Belij-Rammerstorfer, S, Bellamy, D, Bibi, S, Bittaye, M, Clutterbuck, EA, Dold, C, Faust, SN, Finn, A, Flaxman, AL, Hallis, B, Heath, P, Jenkin, D, Lazarus, R, Makinson, R, Minassian, AM, Pollock, KM, Ramasamy, M, Robinson, H, Snape, M, Tarrant, R, Voysey, M, Green, C, Douglas, AD, Hill, AVS, Lambe, T, Gilbert, SC, Pollard, AJ, Oxford COVID Vaccine Trial Group

Booster vaccination against SARS-CoV-2 induces potent immune responses in people with human immunodeficiency virus by Fidler, S, Fox, J, Tipoe, T, Longet, S, Tipton, T, Abeywickrema, M, Adele, S, Alagaratnam, J, Ali, M, Aley, PK, Aslam, S, Balasubramanian, A, Bara, A, Bawa, T, Brown, A, Brown, H, Cappuccini, F, Davies, S, Fowler, J, Godfrey, L, Goodman, AL, Hilario, K, Hackstein, C-P, Mathew, M, Mujadidi, YF, Packham, A, Petersen, C, Plested, E, Pollock, KM, Ramasamy, MN, Robinson, H, Robinson, N, Rongkard, P, Sanders, H, Serafimova, T, Spence, N, Waters, A, Woods, D, Zacharopoulou, P, Barnes, E, Dunachie, S, Goulder, P, Klenerman, P, Winston, A, Hill, AVS, Gilbert, SC, Carroll, M, Pollard, AJ, Lambe, T, Ogbe, A, Frater, J